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Acute kidney injury (AKI) remains a major concern in the field of TAVR and is associated 
with increased mortality, up to 2-8 fold (1). Although the exact mechanism of post-TAVR 
AKI is unknown and seems to be multifactorial, contrast has been reported as a contributing 
factor (2). During TAVR, contrast is used for conventional aortic root angiography, for 
positioning of the TAVR valve device and assessing the peripheral vasculature. To our 
knowledge, for the first time we report transfemoral TAVR performed with zero contrast 
using fluoroscopy and ultrasound guidance. This was done in two patients with symptomatic, 
severe aortic stenosis and significant chronic kidney disease (stage III) who were deemed 
high risk for surgical aortic valve replacement after discussion in the multidisciplinary Heart 
Team meeting. 
EchoNavigator system (Phillips Healthcare, Netherland) is a novel imaging technology which 
allows fusion of real time 2D and 3D echocardiography images on the fluoroscopy screen. It 
has the ability to identify the optimal perpendicular valve view without use of contrast 
(Figure 1), can provide a road map to assist crossing of the aortic valve in difficult cases and 
enables overlay of echocardiographic images on the X-ray screen so that the the soft tissue 
characterization of echocardiography is combined with excellent device visualization of X-
ray to assure precise device deployment. Determining the optimal valve view is a crucial 
prerequisite for accurate positioning of the bioprosthetic valve to avoid potentially life-
threatening complications. Although aortic root angiography is conventionally used to 
identify the valve view, EchoNavigator can be solely used for this purpose. Moreover, to 
further minimise exposure to contrast, 3D transesophageal echocardiography (TEE), which is 
the standard technique in our centre, was used for valve sizing.  
Procedures were done under general anesthesia. As per routine practice in our centre, we 
used a handheld ultrasound device for establishing vascular access in both patients which also 
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allowed assessment of patency of the femoral arteries at the end of the procedure without the 
use of contrast.  
For the first patient, a 27 mm Lotus valve (Boston Scientific) was positioned under combined 
fluoroscopy and fusion imaging guidance (Figure 2).  Intra procedural 2D colour Doppler 
assessment of the positioned valve revealed mild to moderate paravalvular aortic 
regurgitation (AR) resulting from under-expansion of the valve at the site of severely 
calcified non-coronary cusp. Despite attempts to reposition the valve, the paravalvular AR 
remained unchanged. Although there is very limited data on post dilatation of the Lotus valve 
(3), based on previous successful experience in our centre, we decided to post dilate using a 
24 mm balloon, which resulted in complete resolution of the paravalvular AR. A 26 mm 
Sapien 3 (Edwards Lifesciences) valve was used for the second case and deployed under 
fluoro-echo fusion imaging with no parvalvular AR assessed by TEE at the end of the 
procedure (Figure 3). A thorough echocardiographic assessment was performed at the end of 
each procedure to exclude new regional wall motion abnormalities.  
Both patients had an excellent post-procedure recovery and were discharged home on day 
three with no change in renal function, no residual trans-aortic valvular gradient and no 
paravalvular AR.  
Fluoro-echo fusion imaging can be used to minimise the contrast use in patients at high risk 
of developing AKI. The technique has the potential to be routinely used in performing TAVR 
with zero contrast. Further studies are required to assess the impact of zero contrast strategy 
on patients’ outcome.  
Mehdi Eskandari MD 
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No of figures: 3 (all colour)  
Figure captions:  
Figure 1. Identifying the valve view by EchoNavigator 
Figure 2. Positioning of the Lotus valve using EchoNavigator.  
Figure 3. Positioning of the Sapien 3 valve using EchoNavigator. 
 
 
Figure 1 legend. After probe registration, a bi-plane echocardiographic view of the aortic 
valve is acquired. The annulus is marked in two perpendicular views. The Free view of 
EchoNavigator is rotated such that the annulus will look like a line, representing aligned 
aortic valve sinuses. The valve view is shown at the right lower corner of the screen.  
 
Figure 2 legend. Fused real time 3D TEE image on the X-ray screen can be used for 
positioning of the TAVR valve in combination with fluoroscopy. Red line represents annulus, 
blue arrows: aortic valve leaflets, green arrow: Lotus valve radiopaque marker. 
 
Figure 3 legend. Positioning of the Sapien 3 valve using fluoro-echo fusion imaging. Red 
arrows: aortic valve leaflets, blue arrow: Sapien valve radiopaque marker.   
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